Genetic Susceptibility to Bladder Cancer: A Molecular Epidemiology Approach

INTRODUCTION

  • Org Study ID: LAB98-040
  • Secondary ID: LAB98-040, 5P50CA091846-14, H-8577, 5R01CA074880
  • NTC ID: NCT00848289
  • Sponsor: M.D. Anderson Cancer Center
The University of Texas (UT) MD Anderson Cancer Center Official Website

BRIEF SUMMARY

This clinical research study will identify biologic and lifestyle factors which increase a person's risk of developing specific cancer. Researchers propose to conduct a case-control study examining interindividual differences in susceptibility to tobacco carcinogenesis as predictors of bladder cancer risk. We will measure susceptibility to tobacco carcinogenesis and this will include studies of the genetic modulation of carcinogen activation and detoxification and of chromosome sensitivity to tobacco mutagens.

DETAILED DESCRIPTION

Researchers propose to conduct a case-control study examining interindividual differences in susceptibility to tobacco carcinogenesis as predictors of bladder cancer risk. We will measure susceptibility to tobacco carcinogenesis and this will include studies of the genetic modulation of carcinogen activation and detoxification and of chromosome sensitivity to tobacco mutagens.

  • Overall Status
    Recruiting
  • Start Date
    February 10, 1998
  • Phase
  • Study Type
    Observational

PRIMARY OUTCOMES

Primary Outcome 1 - Measure: Comparison of mutagen sensitivity susceptibility assays that quantifies the number of lymphocytic chromatid breaks induced by in vitro exposure to bleomycin and the number of breaks induced by in vitro exposure to a tobacco carcinogen

Primary Outcome 1 - Timeframe: After last subject has completed the study, up to 5 years

CONDITION

  • Bladder Cancer

ELIGIBILITY

Inclusion Criteria:
Subject has a histologically confirmed diagnosis of superficial or muscle-invasive bladder cancer

- Subject is a Texas resident.

- Subject can understand English or a qualified translator is available for the interview.

- Subjects of any age, gender, or ethnicity are eligible to participate in the study.

- Subject consents to participate in the study.
Exclusion Criteria:
Subject has had prior treatment with systemic chemotherapy or radiotherapy in the past 6 months.

- Subject has been diagnosed with superficial or muscle-invasive bladder cancer more than twelve months ago.

Gender: All

Minimum Age: N/A

Maximum Age: N/A

Healthy Volunteers: Accepts Healthy Volunteers

OFFICIAL INFORMATION

Name: Jian Gu, MD

Role: Principal Investigator

Affiliation: M.D. Anderson Cancer Center

Overall Contact

Name: Jian Gu, MD

Phone: 713-792-3020

Email: jiangu@mdanderson.org, tle@mdanderson.org

LOCATION

Facility Status Contact
Facility: MD Anderson Cancer Center
Houston, Texas 77030
United States
Status: Recruiting Contact: N/A